NCT00341055View on ClinicalTrials.gov

A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

PHASE3CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

May 31, 2004

Conditions
AnemiaCancerChemotherapy
Interventions
DRUG

Epoetin alfa

All Listed Sponsors
collaborator

Ortho Biotech Products, L.P.

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00341055 - A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy. | Biotech Hunter | Biotech Hunter